Looks like you found it…from our initial PR of F
Post# of 148268
“Leronlimab will be administered weekly, while TAS-102 and bevacizumab will be given on a 3- or 4-week schedule within a 4-week cycle.”
The MAB will be weekly, the chemos will be at the usual toleration rate.
Investors Hangout: https://investorshangout.com/post/view?id=673...z8sGrjiKZ5